Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the appointment of Donald Haut, Ph.D. as its Chief Business Officer.
“Don is the consummate deal professional and his broad background and expertise across biotechnology, pharmaceuticals and medical devices will be invaluable to us as we capitalize on the NeoCart platform opportunity worldwide,” stated Adam Gridley, President and Chief Executive Officer.
http://ir.histogenics.com/phoenix.zhtml?c=252477&p=irol-newsArticle&ID=2278796
unknownx500
More posts by Erik Lundh
Recent posts from Park Square Executive Search
